NanoliposomeMediated Encapsulation of Chlorella Oil For The Development of A ControlledRelease LipidLowering FormulationFoods
NanoliposomeMediated Encapsulation of Chlorella Oil For The Development of A ControlledRelease LipidLowering FormulationFoods
NanoliposomeMediated Encapsulation of Chlorella Oil For The Development of A ControlledRelease LipidLowering FormulationFoods
Article
Nanoliposome-Mediated Encapsulation of Chlorella
Oil for the Development of a Controlled-Release
Lipid-Lowering Formulation
Lanlan Tu 1,† , Jihao Zeng 1,† , Xue Bai 1 , Ziyun Wu 1 , Jinhong Wu 1, * and Shannan Xu 2, *
Abstract: Chlorella oil nanoliposomes (CO-NLP) were synthesized through ultrasonic injection
with ethanol, and their physicochemical properties and hypolipidemic efficacy were systematically
investigated. The results revealed that the mean particle size of CO-NLP was 86.90 nm and the
encapsulation efficiency (EE) was 92.84%. Storage conditions at 4 ◦ C were conducive to the stability
of CO-NLP, maintaining an EE of approximately 90% even after 10 days of storage. The release
profile of CO-NLP adhered more closely to the first-order kinetic model during in vitro assessments,
exhibiting a slower release rate compared to free microalgae oil. In simulated in vitro digestion
experiments, lipolytic reactions of CO-NLP were observed during intestinal digestion subsequent
to nanoliposome administration. Notably, the inhibitory effect of CO-NLP on cholesterol esterase
activity was measured at 85.42%. Additionally, the average fluorescence intensity of nematodes in the
CO-NLP group was 52.17% lower than in the control group at a CO-NLP concentration of 500 µg/mL,
which suggests a pronounced lipid-lowering effect of CO-NLP. Therefore, the CO-NLP exhibited
characteristics of small and uniform particle size, elevated storage stability, gradual release during
Citation: Tu, L.; Zeng, J.; Bai, X.; Wu,
Z.; Wu, J.; Xu, S.
intestinal digestion, and a noteworthy hypolipidemic effect. These findings designate CO-NLP as a
Nanoliposome-Mediated novel lipid-lowering active product, demonstrating potential for the development of functional foods.
Encapsulation of Chlorella Oil for the
Development of a Controlled-Release Keywords: chlorella oil; nanoliposome; hypolipidemic activity; in vitro digestion simulation
Lipid-Lowering Formulation. Foods
2024, 13, 158. https://doi.org/
10.3390/foods13010158
1. Introduction
Academic Editor: Ali Khoddami
Microalgae oil, specifically chlorella oil, contains linoleic acid, γ-linolenic acid, and
Received: 23 November 2023 various other fatty acids with substantial effects on reducing blood pressure, blood glucose,
Revised: 26 December 2023
and lipids. Additionally, it is abundant in unsaturated fatty acids, including docosahex-
Accepted: 28 December 2023
aenoic acid (DHA), referred to as “brain gold”, promoting the growth and development
Published: 2 January 2024
of brain cells. This makes microalgae oil widely utilized in health products and infant
formula [1]. While it is the only FDA-approved source of DHA supplements for children,
challenges exist in its application [2]. Firstly, due to the unsaturation of fatty acids and poor
Copyright: © 2024 by the authors.
oxidative stability, microalgae oil not only loses its original nutritional value post-oxidation
Licensee MDPI, Basel, Switzerland. but also produces harmful oxidation by-products. Secondly, microalgae oil, being a highly
This article is an open access article hydrophobic molecule with low water solubility, cannot be easily incorporated into most
distributed under the terms and water-based foods and beverages. Finally, microalgae oil often undergoes structural and
conditions of the Creative Commons functional degradation in the acidic gastric environment during digestion, leading to a
Attribution (CC BY) license (https:// significant reduction in in vivo bioavailability.
creativecommons.org/licenses/by/ Nanoliposomes, vesicular lipid bilayer nanocarriers with a spherical shape typically
4.0/). composed of natural, non-toxic phospholipids and cholesterol, present a viable solution.
The advantage of liposomes over nanometer emulsions and microcapsules lies in their
ability to form a system carrying both oil and water [3]. This enables the encapsulation
of both lipophilic and hydrophilic substances in nanoliposomes, resulting in a larger
surface-to-volume ratio. Nanoliposomes have found extensive use in functional foods,
enhancing nutrient solubility, delaying release, and maintaining substance activity due
to their high safety, non-immunological reactivity, biocompatibility, and biodegradabil-
ity [4]. Research indicates nanoliposomes as suitable encapsulants for entrapping and
delivering various vitamins to target cells, enhancing their bioaccessibility and bioavail-
ability [5]. Loading polyphenol-rich herbal extract into nanoliposomes demonstrated
significant glucose-lowering activity in vivo compared to free extract [6]. Liposomes pro-
duced from 4% phospholipids and loaded with astaxanthin exhibited high antioxidant
activity [7], with astaxanthin encapsulated in nanoliposomes achieving an 80.31% high
encapsulation efficiency [8]. In the development of fortified bread as a functional food,
fish oil nanoliposomes did not adversely affect the texture, nutritional content, or sensory
qualities of the fortified bread [9].
To enhance the application stability and bioavailability of chlorella oil, this study opted
for a specific small unilamellar vesicle nanoliposome to encapsulate it. The investigation
delves into physicochemical properties, morphological characteristics, release kinetics,
stability, and lipid-lowering activity. This study aimed to develop a novel functional
chlorella oil carrier, enhancing solubility, improving bioavailability, and achieving better-
controlled release of the encapsulated material. This study provides the theoretical basis
and technical support for the industrial production of functional chlorella oil.
Ltd., Shanghai, China) to generate nanoliposomes, which were then stored in a refrigerator
at 4 ◦ C for further analysis.
In the formula, mfree represents the content of free chlorella oil in the supernatant, and
mtotal represents the content of total chlorella oil in the supernatant.
Foods 2024, 13, 158 4 of 17
where Ve is the sampling volume (10 mL), V0 is the total volume (200 mL), Ci and Ct are
chlorella oil concentrations in the solution at different release times (mg/L), and m0 is the
mass of encapsulated oil in liposomes (mg).
Four release kinetic equations were selected for release analysis: the zero-order kinetic
equation, the first-order kinetic equation, the Higuchi plane diffusion equation, and the
Retger-Peppas equation. The curves were fitted to evaluate the accuracy of the fit, and then
the in vitro release type of CO-NLP was determined to elucidate the pattern of chlorella oil
liposome release.
can break down, emit free fatty acids, and lower the pH value of the environment in the
presence of trypsin. Each digestion stage was terminated by transferring the digest to
a glass tube and subjecting it to agitation at 85 ◦ C for 5 min, followed by cooling in an
ice water bath. The amount of NaOH consumed served as a measure of the rate of FFA
release [4].
The rate of fat release (FFA)% was determined using the Formula (3):
where MNaOH is the concentration of NaOH solution (0.25 mol/L), VNaOH is the volume of
NaOH solution used (L), MLipid is the average molecular weight of fat molecules (g/mol),
and its value is 923.08 g/mol, and mLipid is the total mass of fat in liposomes (g).
2.12. Calculation of the Particle Dimensions and Zeta Potential of Digestion Byproducts from
CO-NLP
Prior to sampling, dilution of the sample was conducted in a suitable aqueous solution
to mitigate any scattering effects. The system was then stirred at 1200 r/min to ensure
consistency. Subsequently, the mean particle size and zeta potential in both gastric and
intestinal digests were determined utilizing a nanoparticle size and zeta potential analyzer.
Table 1. The quantity of additive agents used to evaluate cholesterol esterase inhibitory activity.
Where A1 is the absorbance of the blank group (with the sample solution substituted
with an equal volume of buffer), A2 is the absorbance of the blank control group (with both
the sample solution and enzyme solution substituted with an equal volume of buffer), A3 is
the absorbance of the sample group, and A4 is the absorbance of the sample control group
(with the enzyme solution substituted with an equal volume of buffer).
1.9
1.7
1.5
1.3
A400nm
1.1
0.9
0.7
0.5
y = 11.401x + 0.0054
0.3 R² = 0.9998
0.1
0 0.02 0.04 0.06 0.08 0.1 0.12 0.14 0.16
Microalgae oil concentration(mg/mL)
Figure 1.1.
Figure AA standard curve
standard is is
curve used forfor
used quantifying chlorella
quantifying chlorellaoiloilconcentration.
concentration.
Table2 2provides
Table providesananin-depth
in-depthanalysis
analysisofofthe
thefatty
fattyacid
acidcomposition
compositioninin chlorella
chlorella oil.
oil.
Theresults
The resultshighlight
highlighteicosapentaenoic
eicosapentaenoicacidacid(EPA)
(EPA)asasthe thepredominant
predominantunsaturated
unsaturatedfatty
fatty
acidpresent
acid presentininthe
thechlorella
chlorellafatty
fattyacid
acidextract,
extract,closely
closelyfollowed
followedbybythe
themonounsaturated
monounsaturated
fatty acids palmitoleic acid and docosahexaenoic acid (DHA). Additionally,
fatty acids palmitoleic acid and docosahexaenoic acid (DHA). Additionally, palmitic palmiticacid
acid
and myristicin were identified as the primary constituents in the sample. These findings
unequivocally confirm the presence of unsaturated fatty acids (UFAs) in the chlorella oil
extracts utilized in the current study, aligning with prior research [15].
Foods 2024, 13, 158 7 of 17
(a)
(b)
Figure 2. Diameter distribution (a) and electron micrographs illustrating the morphology (b) with a
scale bar of 100 nm (left) and 50 nm (right) of CO-NLP.
Figure 3. Storage stability assessment of CO-NLP over time, with panels depicting (A) EE, (B) Size,
Figure3.3.Storage
Figure Storagestability
stabilityassessment
assessmentof
ofCO-NLP
CO-NLPover
overtime,
time,with
withpanels
panelsdepicting
depicting(A)
(A)EE,
EE,(B)
(B)Size,
Size,
(C)
(C)Zeta
ZetaPotential,
Potential,and
and(D)
(D)PDI.
PDI.
(C) Zeta Potential, and (D) PDI.
continuous addition of NaOH solution to neutralize free fatty acids and maintain the pH
value of the digestion system constant at 7.0.
(a)
(b)
(c)
Figure 6. Assessment of the bioavailability and digestive properties of CO-NLP. (a) Kinetic curves
illustrating the lipolysis of CO-NLP, Where the black curve represents the CO-NLP sample and
the red curve represents the simple physical mixing emulsion made of microalgae oil and the
embedding material; (b) Particle size of chlorella oil liposomes during digestion, among them, the
red curve represents the undigested samples, the green curve represents the samples obtained after
oral simulation digestion, the blue curve represents the samples obtained after gastric simulation
digestion, and the black curve represents the samples obtained after intestinal simulation digestion;
(c) Zeta potential changes during simulated digestion, where the ns refers to no significant difference
between groups, while ** refers to significant difference between groups (p < 0.05).
Foods 2024, 13, 158 12 of 17
As depicted in the figure, the amount of free fatty acids released into the intestinal
fluid environment steadily increased with the duration of digestion. The hydrolysis rate of
CO-NLP experienced rapid escalation before stabilizing, and the release rate of free fatty
acids from CO-NLP and the physically hybrid emulsion group (the formulation is the same
as that of the nano-liposomes but the liposome structure is not formed) followed a similar
trend. Within the initial 60 min of enteric digestion, the physically hybrid emulsion group
exhibited a significantly higher release rate of free fatty acids compared to the CO-NLP
group. However, after 60 min, the release rate of CO-NLP started to surpass that of the
physically hybrid emulsion group. At the end of the simulated intestinal fluid digestion,
the free fatty acid release rate of CO-NLP was 82.57 ± 1.45%, compared to 66.26 ± 1.87%
in the hybrid emulsion group, indicating that CO-NLP is more proficient at undergoing
lipolysis reactions in intestinal digestion.
The large specific surface area and weak spatial site resistance of nanotransport carriers,
such as nanoliposomes, facilitate enhanced interaction between pancreatic lipase and
encapsulated lipids, leading to a more efficient lipolytic reaction [26]. Additionally, the
primary constituents of pancreatic enzymes in the small intestine—lipase, phospholipase
A2, and cholesterol esterase—can break down lipids. Pancreatic lipase facilitates the
hydrolysis reaction of fatty acids in phospholipids, resulting in the liberation of fatty
acids and monoacyl lysophospholipids [27]. The disruption of the phospholipid emulsion
layer structure by this digestion product leads to a further increase in the release rate
of free fatty acids from liposomes [28]. Phospholipase A2 facilitates the breakdown of
the sn-2 ester bond in phospholipids, resulting in the production of glycerophosphate
and lysophospholipids; furthermore, cholesterol esterase, also referred to as bile salt-
stimulating lipase, can hydrolyze phospholipids [29]. Additionally, bile salts have the ability
to stimulate cholesterol enzymes, enabling the breakdown of lecithin and the formation
of unbound fatty acids, resulting in a considerably elevated release rate of free fatty acids
from CO-NLP compared to the control group in the later stages of digestion.
3.2.6. Changes in Particle Size and Zeta Potential during Digestion of CO-NLP
The determination of particle size in the digestive product serves as a pivotal indicator
of the digestive system, enabling the assessment of chlorella oil absorption status during the
digestive process. Zeta potential, as a measure of the charge count on a particle’s surface,
is commonly employed to signify the stability of a digestion system. Both particle size
and zeta potential play a critical role in determining the physicochemical properties of the
system throughout digestion. Figure 6b illustrates the mean particle size and zeta potential
of the digestion products at various stages of digestion.
Subsequent to the in vitro digestion of CO-NLP, significant alterations manifested in
their composition, structure, and stability. As depicted in Figure 6b, the treatment with
simulated oral, simulated stomach, and simulated intestinal fluids induced fluctuations
in the average particle size of CO-NLP. In the simulated oral phase, CO-NLP underwent
flocculation, resulting in an increased particle size of 89.35 ± 1.38 nm. During the stomach
phase, CO-NLP exhibited a higher flocculation rate, yielding an average particle size of
122.00 ± 7.81 nm for chlorella oil liposomes. Conversely, in the simulated intestinal phase, a
reduction in particle size occurred, with an average size of 97.69 ± 0.60 nm for CO-NLP. The
absorption of pepsin into the system transpires as CO-NLP traverses simulated gastric juice.
The low pH in gastric juice, coupled with the absence of electrostatic repulsion or spatial site
resistance, ensures system stability, causing aggregation and an increase in particle size [30].
CO-NLP and their encapsulations undergo hydrolysis by pancreatic lipase and bile salts in
simulated intestinal fluid during the simulated intestinal phase. The resultant free fatty
acids, bile salts, and phospholipids form a colloidal structure, potentially causing a decrease
in the mean particle size of CO-NLP. Simultaneously, augmented electrostatic repulsion
hinders oil droplet gathering, leading to a reduction in system particle size post-intestinal
digestion [31]. The decrease in liposome particle size in the small intestinal environment
Foods 2024, 13, 158 13 of 17
may be attributed to the presence of bile salts, which possess surfactant properties that
disrupt the phospholipid bilayer of liposomes [32].
Zeta potential is employed to calculate the surface charge of particles, and in the
context of CO-NLP solution testing through in vitro digestion, alterations in zeta poten-
tial indicate a shift in the system’s interfacial makeup, as evident in Figure 6c. With the
progression of digestion, there is a tendency for the zeta potential to decrease and then
increase. Following simulated oral cavity digestion, a slight decline in the zeta potential
of CO-NLP was observed, presumably influenced by the anionic element (mucin) present
in saliva affecting the particles’ electrical characteristics [1]. After the simulated stomach
stage, a significant decrease in the particles’ negative charge occurs due to the low pH
and high ionic strength of the system post-digestion by simulated gastric juice. The acidic
environment induces protonation of free fatty acids (-COOH), decreasing the overall charge
on the particle’s surface, while strong ions create an electrostatic barrier [33]. The zeta
potential experiences a substantial decrease due to gastric juice digestion. Finally, the
zeta potential of CO-NLP in the simulated intestine phase increases to 26.73 ± 1.81 mV.
Pancreatic lipase breakdown of microalgal oil produces anionic free fatty acids and mono-
glycerides, increasing the net charge of CO-NLP in simulated intestinal fluid. Consequently,
the zeta potential exhibits a substantial increase in its absolute value [34]. Makino et al. [35]
have demonstrated that the hydrophobic groups of phospholipids, when exposed to bile
salts, can migrate to the surface of aqueous solutions, potentially causing an increase in the
negative charge on the surface of liposomes after small intestinal digestion. Additionally,
hydrolysis of phospholipids from liposome wall materials can lead to an increase in the
negative charge.
Figure 7.
Figure 7. The
The inhibitory
inhibitoryactivity
activityofofthe
theCO-NLP
CO-NLPand
andthe blank
the nanoliposome
blank on on
nanoliposome thethe
cholesterol es- esterase.
cholesterol
terase.
3.3.2. Assessment of the Hypolipidemic Impact In Vivo of CO-NLP in C. elegans MODEL
3.3.2. Assessment of the Hypolipidemic Impact In Vivo of CO-NLP in C. elegans MODEL
C. elegans is a good model organism for lipid storage studies due to its possession of
C. elegans
regulatory is a good
factors andmodel organism
metabolic for lipidakin
pathways storage studiesgoverning
to those due to its possession of
adipose deposition
regulatory factors and metabolic pathways akin to those governing
and related metabolic diseases in mammals. Numerous lipid deposition mutants have adipose deposition
and related metabolic diseases in mammals. Numerous lipid deposition mutants have
been generated in C. elegans, including the dhs-3::gfp mutant, which manifests green
been generated in C. elegans, including the dhs-3::gfp mutant, which manifests green flu-
fluorescence on lipid droplet surfaces, facilitating the facile observation of changes in lipid
orescence on lipid droplet surfaces, facilitating the facile observation of changes in lipid
deposition. Therefore,wewe
deposition. Therefore, employed
employed dhs-3::gfp
dhs-3::gfp mutants
mutants to observe
to observe the impact
the impact of CO-NLP of CO-NLP
on
on lipid accumulationinin
lipid accumulation C.C. elegans,
elegans, with with
imageimage analysis
analysis performed
performed using J.Image
using Image The J. The
results depictedininFigure
results depicted Figure 8 indicate
8 indicate thatthat
the the
meanmean fluorescence
fluorescence intensity
intensity of the blank
of the blank
nanoliposome
nanoliposome group group was
was 2.540
2.540 ± 0.043,
± 0.043, whereaswhereas that
that of the ofµg/mL
500 the 500 µg/mL
CO-NLP CO-NLP
group was group
was ± 0.02±(p0.02
1.22 1.22 (p < 0.001),
< 0.001), signifyingsignifying a reduction
a reduction of nearly of nearly
52.17%. 52.17%.
This This result
result suggests thatsuggests
CO-NLP
Foods 2024, 13, x that
FOR CO-NLP
PEER attenuates
REVIEW lipid accumulation
attenuates in C. elegans,
lipid accumulation in C. implying a potentiala reduction
elegans, implying potential in in
reduction in15 of 18
vivo
in vivoadipose
adiposedeposition.
deposition.
(a) (b)
(c) (d)
Figure 8.images
Figure 8. Representative Representative images
of dhs-3::gfp of dhs-3::gfp
fluorescence influorescence in worms
worms induced induced
by blank by blank nanolipo-
nanoliposomes
somes and CO-NLP. (a) Blank nanoliposome group (dark field, 100 px). (b) DMSO group (bright
and CO-NLP. (a) Blank nanoliposome group (dark field, 100 px). (b) DMSO group (bright field,
field, 100 px). (c) CO-NLP group (dark field). (d) CO-NLP group (bright field).
100 px). (c) CO-NLP group (dark field). (d) CO-NLP group (bright field).
4. Conclusions
The inherent hydrophobic characteristics of chlorella oils, combined with their lim-
ited water solubility, impede their integration into the majority of water-based food and
beverage products. However, the use of liposome encapsulation facilitates their uniform
dispersion in water.
In this study, chlorella oil nanoliposomes (CO-NLP) were synthesized employing a
Foods 2024, 13, 158 15 of 17
4. Conclusions
The inherent hydrophobic characteristics of chlorella oils, combined with their lim-
ited water solubility, impede their integration into the majority of water-based food and
beverage products. However, the use of liposome encapsulation facilitates their uniform
dispersion in water.
In this study, chlorella oil nanoliposomes (CO-NLP) were synthesized employing a
method involving ethanol injection and ultrasonication. The CO-NLP demonstrated a
phospholipid bilayer structure, boasting an encapsulation efficiency of 92.84 ± 1.14%, an
average particle size of 86.90 ± 0.74 nm, and a PDI of 0.19 ± 0.01. TEM revealed that the
CO-NLP exhibited a spherical morphology with consistent size, maintaining exceptional
stability at 4 ◦ C. In vitro release experiments revealed a gradual release effect of CO-NLP,
aligning closely with the primary release kinetic model. Simulated in vitro digestion
experiments underscored the heightened efficacy of CO-NLP in lipid breakdown during
intestinal digestion. The inhibition rate of cholesterol esterase by CO-NLP was determined
to be 85.42 ± 0.25% at a concentration of 500 µg/mL. Notably, the average fluorescence
intensity of C. elegans in the CO-NLP group was 52.17% lower than that of the control
group, indicating the superior hypolipidemic function of CO-NLP.
These findings provide a solid theoretical foundation for the development of hypolipi-
demic functional foods. Liposome technology holds promise for enhancing the stability of
chlorella oil and augmenting its bioavailability through controlled release, thereby foster-
ing the integration of chlorella oil into food applications. The advancements in this study
offer crucial technical support for the practical utilization of CO-NLP, opening up a broad
spectrum of potential applications.
Supplementary Materials: The following supporting information about the preparation technology
of chlorella oil nanoliposomes can be downloaded: https://www.mdpi.com/article/10.3390/foods1
3010158/s1, Figure S1: Effect of lecithin and β-sitosterol mass ratio on the EE (a), particle size, and
PDI (b) of CO-NLP; Figure S2: Effect of lecithin and chlorella oil mass ratio on the EE (a), particle size,
and PDI (b) of CO-NLP; Figure S3: Effect of Tween-80 amount added on the EE (a), particle size, and
PDI (b) of CO-NLP; Figure S4: Effect of PBS buffer pH on the EE (a), size, and PDI (b) of CO-NLP;
Figure S5: Effect of ultrasonic duration on the EE (a), size, and PDI (b) of CO-NLP; Figure S6: Effect of
ultrasonic power on the EE (a), size, and PDI (b) of CO-NLP; Table S1: Plackett-Burman design matrix
and corresponding results for CO-NLP encapsulation; Table S2: Analysis of variance for Plackett-
Burman design investigating the impact of various process conditions on the encapsulation rate of
CO-NLP; Table S3: Analysis of variance for the Plackett-Burman design examining the influence
of different process conditions on the particle size of CO-NLP; Table S4: Design and results of the
Box-Behnken experiment; Table S5: Design and results of the Box-Behnken experiment; Table S6:
Analysis of variance for the developed regression equation; Table S7: Analysis of variance for the
developed regression equation; Table S8: Verification of experimental results for CO-NLP.
Author Contributions: L.T.: Conceptualization, Data curation, Investigation, Methodology, Writing—
original draft; J.Z.: Formal analysis, Methodology, visualization, Writing—review and editing,
Writing—original draft; X.B.: Methodology and Software; Z.W.: Methodology and Formal analysis;
J.W.: Conceptualization, Data curation, Funding acquisition, Investigation, Methodology, Writing—
review and editing; S.X.: Conceptualization, Funding acquisition, Writing—review. All authors have
read and agreed to the published version of the manuscript.
Funding: This work was funded by the Financial Fund of the Ministry of Agriculture and Rural
Affairs, P. R. China (NFZX2021); the Bayannaoer City National Industrial High-Tech Industrial
Demonstration Zone key project of “Science and Technology to promote Inner Mongolia development”
(grant number NMKJXM202209-2); the Central Public-interest Scientific Institution Basal Research
Fund, CAFS (No. 2023TD16).
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: Data is contained within the article and Supplementary Materials.
Foods 2024, 13, 158 16 of 17
References
1. Salvia-Trujillo, L.; Qian, C.; Martín-Belloso, O.; McClements, D.J. Influence of particle size on lipid digestion and β-carotene
bioaccessibility in emulsions and nanoemulsions. Food Chem. 2013, 141, 1472–1480. [CrossRef] [PubMed]
2. Enamala, M.K.; Enamala, S.; Murthy, C.; Jagadish, D.; Rajasri, Y.; Bhulakshmi, K.; Tirumala, V.A.; Jeevitha, V.; Chandrasekhar,
K. Production of biofuels from microalgae-a review on cultivation, harvesting, lipid extraction, and numerous applications of
microalgae. Renew. Sustain. Energy Rev. 2018, 94, 49–68. [CrossRef]
3. Sarabandi, K.; Seid, M.J.; Maryam, M.; Zahra, A.; Akram, P.; Maryam, K.H. Production of Reconstitutable Nanoliposomes Loaded
with Flaxseed Protein Hydrolysates: Stability and Characterization. Food Hydrocoll. 2019, 96, 442–450. [CrossRef]
4. Zhu, Y.; Zhou, Y.; Tian, T.; Wang, Z.; Qi, B.; Zhang, X.; Liu, J.; Li, Y.; Jiang, L.; Wang, Z. In vitro simulated digestion and
microstructure of peppermint oil nanoemulsion. J. Oleo Sci. 2019, 68, 863–871. [CrossRef] [PubMed]
5. Masoud, A.M.; Parastou, F.; Parisa, A.; Azam, A.; Mohammad, Y.; Marjan, G.; Seyede, M.H. Encapsulation of vitamins using
nanoliposome: Recent advances and perspectives. Adv. Pharm. Bull. 2023, 13, 48–68.
6. Wickramasinghe, A.S.D.; Attanayake, A.P.; Kalansuriya, P. Herbal extracts encapsulated nanoliposomes as potential glucose-
lowering agents: An in vitro and in vivo approach using three herbal extracts. J. Pharm. Sci. 2023, 112, 2538–2551. [CrossRef]
7. Darachai, P.; Limpawattana, M.; Hawangjoo, M.; Klaypradit, W. Effects of shrimp waste types and their cooking on properties of
extracted astaxanthin and its characteristics in liposomes. J. Food Nutr. Res. 2019, 7, 530–536. [CrossRef]
8. Pan, L.; Wang, H.; Gu, K. Nanoliposomes as vehicles for astaxanthin: Characterization, in vitro release evaluation and structure.
Molecules 2018, 23, 2822. [CrossRef]
9. Ojagh, S.M.; Hasani, S. Characteristics and oxidative stability of fish oil nano-liposomes and its application in functional bread. J.
Food Meas. Charact. 2018, 12, 1084–1092. [CrossRef]
10. Chen, Y.; Shuang, L.; Yuan, Y.J. Quality assessment of blended vegetable oil based on fatty acid index. J. Food Saf. Qual. 2021, 12,
2073–2079.
11. Wang, J.L.; Dong, X.Y.; Wei, F.; Zhong, J.; Liu, B.; Yao, M.H.; Yang, M.; Zheng, C.; Quek, S.Y.; Chen, H. Preparation and
characterization of novel lipid carriers containing microalgae oil for food applications. J. Food Sci. 2014, 79, 169–177. [CrossRef]
[PubMed]
12. Smith, M.C.; Crist, R.M.; Clogston, J.D.; McNeil, S.E. Zeta potential: A case study of cationic, anionic, and neutral liposomes.
Anal. Bioanal. Chem. 2017, 409, 5779–5787. [CrossRef] [PubMed]
13. Xu, J.; Jiang, S.; Liu, L.; Zhao, Y.; Zeng, M. Encapsulation of oyster protein hydrolysates in nanoliposomes: Vesicle characteristics,
storage stability, in vitro release, and gastrointestinal digestion. J. Food Sci. 2021, 86, 960–968. [CrossRef] [PubMed]
14. Su, J.; Ma, C.; Yang, L.; Wang, H.; Gao, C.; Nie, R. Inhibition of pancreatic cholesterol esterase activities and cholesterol micelle of
EGCG and quercetin. Sci. Technol. Food Ind. 2015, 36, 346–349.
15. Lv, W.; Xu, D. Docosahexaenoic acid delivery systems, bioavailability, functionality, and applications: A review. Foods 2022, 11,
2685. [CrossRef] [PubMed]
16. Li, T.; Nowell, C.J.; Cipolla, D.; Rades, T.; Boyd, B.J. Direct comparison of standard transmission electron microscopy and
cryogenic-TEM in imaging nanocrystals inside liposomes. Mol. Pharm. 2019, 16, 1775–1781. [CrossRef] [PubMed]
17. Rattanawongwiboon, T.; Soontaranon, S.; Hemvichian, K.; Lertsarawut, P.; Laksee, S.; Picha, R. Study on particle size and size
distribution of gold nanoparticles by TEM and SAXS. Radiat. Phys. Chem. 2022, 191, 109842. [CrossRef]
18. Safi, C.; Zebib, B.; Merah, O.; Pontalier, P.Y.; Vaca-Garcia, C. Morphology, composition, production, processing and applications
of chlorella vulgaris: A review. Renew. Sustain. Energy Rev. 2014, 35, 265–278. [CrossRef]
19. Wang, F.L.; Pu, C.F.; Liu, M.Y.; Li, R.S.; Yue, S.; Tang, W.T.; Sun, Q.J.; Qin, T. Fabrication and characterization of walnut peptides-
loaded proliposomes with three lyoprotectants: Environmental stabilities and antioxidant/antibacterial activities. Food Chem.
2022, 366, 130643. [CrossRef]
20. Xiao, X.X.; Xue, H.W.; Yu, Z.L.; He, J.H. Incorporation of the sterol from camellia oil deodorant distillate into vitamin C liposomes:
Vesicle characteristics, stability, release, and bioavailability. Food Biophys. 2023, 18, 10–22. [CrossRef]
21. Peschka, R.; Dennehy, C.; Szoka, J.F.C. A simple in vitro model to study the release kinetics of liposome encapsulated material. J.
Control. Release 1998, 56, 41–51. [CrossRef]
22. Tian, S.J.; Zhang, B.B.; Wang, L.; Chang, H.M. Study on stability and release performance of flaxseed oil precursor liposomes. J.
Chin. Cereals Oils Assoc. 2019, 34, 92–106.
23. Zeng, L.; An, L.; Wu, X. Modeling drug-carrier interaction in the drug release from nanocarriers. J. Drug Deliv. 2011, 2011, 370308.
[CrossRef] [PubMed]
24. Charoensit, P.; Kawakami, S.; Higuchi, Y.; Yamashita, F.; Hashida, M. Enhanced Growth Inhibition of Metastatic Lung Tumors
by Intravenous Injection of ATRA-cationic Liposome IL-12 PDNA Complexes in Mice. Cancer Gene Ther. 2010, 17, 512–522.
[CrossRef] [PubMed]
25. Shi, J.; Jun, S.; De, S.F.; Pei, Y.; Shao, K.C. Stimuli-responsive Hybrid Composites Based on CaCO3 Microparticles and Smart
Polyelectrolytes for Controllable Drug Delivery. Polym. Bull. 2014, 71, 1857–1873. [CrossRef]
26. Raj, S.; Khurana, S.; Choudhari, R.; Kesari, K.K.; Kamal, M.A.; Garg, N.; Ruokolainen, J.; Das, B.C.; Kumar, D. Specific targeting
cancer cells with nanoparticles and drug delivery in cancer therapy. Semin. Cancer Biol. 2021, 69, 166–177. [CrossRef] [PubMed]
Foods 2024, 13, 158 17 of 17
27. Pan, Y.; Nitin, N. Real-time measurements to characterize dynamics of emulsion interface during simulated intestinal digestion.
Colloids Surf. B Biointerfaces 2016, 141, 233–241. [CrossRef]
28. Haas, G.H.D.; Sarda, L.; Roger, J. Positional specific hydrolysis of phospholipids by pancreatic lipase. BBA-Lipids Lipid Metab.
1965, 106, 638–640. [CrossRef]
29. Howles, P.N.; Carter, C.P.; Hui, D.Y. Dietary free and esterified cholesterol absorption in cholesterol esterase (bile salt-stimulated
lipase) gene-targeted mice. J. Biol. Chem. 1996, 271, 7196–7202. [CrossRef]
30. He, S.; Gu, C.; Wang, D.; Xu, W.; Wang, R.; Ma, Y. The stability and in vitro digestion of curcumin emulsions containing Konjac
glucomannan. LWT 2020, 117, 108672. [CrossRef]
31. Kossena, G.A.; Boyd, B.J.; Porter, C.J.H.; Charman, W.N. Separation and characterization of the colloidal phases produced on
digestion of common formulation lipids and assessment of their impact on the apparent solubility of selected poorly water-soluble
drugs. J. Pharm. Sci. 2003, 92, 634–648. [CrossRef] [PubMed]
32. O’Connor, C.J.; Wallace, R.G.; Iwamoto, K.; Taguchi, T.; Sunamoto, J. Bile salt damage of egg phosphatidylcholine liposomes.
BBA-Biomembr. 1985, 817, 95–102. [CrossRef] [PubMed]
33. Zou, L.; Zheng, B.; Liu, W.; Liu, C.; Xiao, H.; McClements, D.J. Enhancing nutraceutical bioavailability using excipient emulsions:
Influence of lipid droplet size on solubility and bioaccessibility of powdered curcumin. J. Funct. Foods 2015, 15, 72–83. [CrossRef]
34. Ahmed, K.; Li, Y.; McClements, D.J.; Xiao, H. Nanoemulsion- and emulsion-based delivery systems for curcumin: Encapsulation
and release properties. Food Chem. 2012, 132, 799–807. [CrossRef]
35. Makino, K.; Yamada, T.; Kimura, M.; Oka, T.; Ohshima, H.; Kondo, T. Temperature- and ionic strength-induced conformational
changes in the lipid head group region of liposomes as suggested by zeta potential data. Biophys. Chem. 1991, 41, 175–183.
[CrossRef] [PubMed]
36. Koyande, A.K.; Chew, K.W.; Rambabu, K.; Tao, Y.; Chu, D.T.; Show, P.L. Microalgae: A potential alternative to health supplemen-
tation for humans. Food Sci. Hum. Wellness 2019, 8, 16–24. [CrossRef]
37. Regueiras, A.; Huguet, Á.; Conde, T.; Couto, D.; Domingues, P.; Domingues, M.R.; Costa, A.M.; Silva, J.L.D.; Vasconcelos, V.;
Urbatzka, R. Potential anti-obesity, anti-steatosis, and anti-inflammatory properties of extracts from the microalgae chlorella
vulgaris and chlorococcum amblystomatis under different growth conditions. Mar. Drugs 2022, 20, 9. [CrossRef]
38. Yang, Y.; Ge, S.; Chen, Q.; Lin, S.; Zeng, S.; Tan, B.K.; Hu, J. Chlorella unsaturated fatty acids suppress high-fat diet-induced
obesity in C57/BL6J mice. J. Food Sci. 2022, 87, 3644–3658. [CrossRef]
39. Zhang, H.; Wu, Q.; Wei, X.; Qin, X. Pancreatic lipase and cholesterol esterase inhibitory effect of Camellia nitidissima Chi flower
extracts in vitro and in vivo. Food Biosci. 2020, 37, 100682. [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual
author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to
people or property resulting from any ideas, methods, instructions or products referred to in the content.